PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results
July 26 2021 - 8:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies based on
the Company’s proprietary Versamune® T-cell activating technology,
will release financial results for the second quarter of 2021 on
Thursday, August 12, 2021, before the market opens. Following the
release, management will host a conference call to review the
company’s financial results and provide a business update.
The conference call is scheduled to begin at 8:00
am ET on Thursday, August 12, 2021. Participants should dial
877-407-3088 (United States) or 201-389-0927 (International) and
mention PDS Biotechnology. A live webcast of the conference call
will also be available on the investor relations page of the
Company's corporate website at www.pdsbiotech.com.
After the live webcast, the event will be archived on PDS
Biotech’s website for 6 months. In addition, a telephonic replay of
the call will be available for 6 months. The replay can be accessed
by dialing 877-660-6853 (United States) or 201-612-7415
(International) with confirmation code 13721612.
About PDS BiotechnologyPDS Biotech is a
clinical-stage immunotherapy company developing a growing pipeline
of cancer immunotherapies based on the Company’s proprietary
Versamune® T-cell activating technology platform. Our
Versamune®-based products have demonstrated the potential to
overcome the limitations of current immunotherapy by
inducing in vivo, large quantities of high-quality, highly
potent polyfunctional tumor specific CD4+ helper and CD8+ killer
T-cells capable of targeting and killing tumors. Our
immuno-oncology product candidates are initially being studied in
combination therapy to potentially enhance efficacy without
compounding toxicity across a range of cancer types. The company’s
lead investigational cancer immunotherapy product PDS0101 is
currently in three (3) Phase 2 clinical studies in HPV-associated
cancers. Interim data for the company’s most advanced Phase 2 trial
was reported in an oral presentation at the recent American Society
of Clinical Oncology (ASCO) on June 7, 2021. The interim results
demonstrated strong efficacy in treating the cancer in patients
with advanced, treatment-resistant HPV16-positive anal, cervical,
head and neck, vaginal and vulvar cancers. PDS Biotech has
developed multiple therapies, based on combinations of
Versamune® and disease-specific antigens, designed to train
the immune system to better recognize diseased cells and
effectively attack and destroy them. The company’s pipeline
products address various cancers including breast, colon, lung,
prostate and ovarian cancers. To learn more, please
visit www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
CONTACT: Media & Investor Relations Contact:Deanne
RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404) 736-3838Email:
pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2023 to Sep 2024